The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Bristol Myers and BioNTech are teaming up to develop and commercialize BNT327, a cancer therapy with blockbuster ambition.

A new COVID variant - NB 1.8.1 - is creeping across California; here are the symptoms to watch for, and vaccinations you'll ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

A new COVID variant - NB 1.8.1 - is creeping across the country; here are the symptoms to watch for, and vaccinations you'll ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

Sanofi and BMS paid big money for rare disease and cancer assets, while Regeneron got in the obesity game; AstraZeneca, Gilead and Amgen shone at ASCO; RFK Jr. and the CDC appeared to disagree over ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Truist Securities analysts raised the price target on BioNTech SE (NASDAQ:BNTX) from $151 to $155 and kept a “Buy” rating.